PAPZIMEOS (zopapogene imadenovec-drba)
Recurrent Respiratory Papillomatosis (RRP)
ApprovedCommercial Launch
Key Facts
Indication
Recurrent Respiratory Papillomatosis (RRP)
Phase
Approved
Status
Commercial Launch
Company
About Precigen
Precigen is a commercial-stage biopharmaceutical company focused on developing precision gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases. The company achieved a critical inflection point with the FDA approval of PAPZIMEOS in August 2025 for recurrent respiratory papillomatosis (RRP). Its strategy is built on two proprietary technology platforms—AdenoVerse® for viral vector gene delivery and UltraCAR-T® for next-generation cell therapy—designed to overcome key limitations in the field and create a sustainable pipeline of advanced therapeutics.
View full company profileTherapeutic Areas
Other Recurrent Respiratory Papillomatosis (RRP) Drugs
| Drug | Company | Phase |
|---|---|---|
| INO-3107 | Inovio Pharmaceuticals | BLA Submitted |